Literature DB >> 26361716

Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU).

D H Dreyfus1.   

Abstract

Acute infection with viral pathogens in the herpesviridae family can trigger acute urticaria, and reactivation of herpesviridae is associated with cutaneous urticarial-like syndromes such as drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS). Reactivation of latent herpesviridae has not been studied systematically in chronic idiopathic/spontaneous urticaria (CIU). This review proposes that CIU is an inflammatory disorder with autoimmune features (termed 'CVU' for chronic viral urticaria), based on serology consistent with the hypothesis that reactivation of a latent herpesvirus or -viruses may play a role in CIU. Serology obtained from a cohort of omalizumab (Xolair)-dependent patients with severe CIU was consistent with previous HHV-6 infection, persistent viral gene expression and replication. CIU patients also exhibited serological evidence of increased immune response to HHV-4 (Epstein-Barr virus, or EBV) but not all CIU patients were infected with EBV. These observations, combined with case reports of CIU response to anti-viral therapy, suggest that HHV-6, possibly interacting with HHV-4 in cutaneous tissues, is a candidate for further prospective study as a co-factor in CIU.
© 2015 British Society for Immunology.

Entities:  

Keywords:  DRESS; Th2 cytokine; chronic urticaria; herpesviridae; omalizumab; virokine; virome

Mesh:

Substances:

Year:  2015        PMID: 26361716      PMCID: PMC4711162          DOI: 10.1111/cei.12704

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Successful use of valciclovir in a case of recurrent urticaria associated with genital herpes.

Authors:  A Khunda; M Kawsar; J M Parkin; G E Forster
Journal:  Sex Transm Infect       Date:  2002-12       Impact factor: 3.519

2.  Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.

Authors:  David H Dreyfus
Journal:  Ann Allergy Asthma Immunol       Date:  2008-06       Impact factor: 6.347

3.  Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome.

Authors:  George J Xu; Tomasz Kula; Qikai Xu; Mamie Z Li; Suzanne D Vernon; Thumbi Ndung'u; Kiat Ruxrungtham; Jorge Sanchez; Christian Brander; Raymond T Chung; Kevin C O'Connor; Bruce Walker; H Benjamin Larman; Stephen J Elledge
Journal:  Science       Date:  2015-06-05       Impact factor: 47.728

4.  Presence of HHV-6 genome in spermatozoa in a context of couples with low fertility: what type of infection?

Authors:  A N Godet; G Soignon; H Koubi; P Bonnafous; H Agut; C Poirot; A Gautheret-Dejean
Journal:  Andrologia       Date:  2014-05-20       Impact factor: 2.775

Review 5.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic') urticaria.

Authors:  A B Kay; P Clark; M Maurer; S Ying
Journal:  Br J Dermatol       Date:  2015-04-12       Impact factor: 9.302

7.  Discovery and biological characterization of two novel pig-tailed macaque homologs of HHV-6 and HHV-7.

Authors:  Jeannette P Staheli; Michael R Dyen; Patrick Lewis; Serge Barcy
Journal:  Virology       Date:  2014-10-31       Impact factor: 3.616

Review 8.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 9.  The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.

Authors:  Tse Wen Chang; Christina Chen; Chien-Jen Lin; Martin Metz; Martin K Church; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2014-06-17       Impact factor: 10.793

Review 10.  Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.

Authors:  Katie D White; Wen-Hung Chung; Shuen-Iu Hung; Simon Mallal; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

View more
  4 in total

Review 1.  Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Authors:  Susanne Radonjic-Hoesli; Kathrin Scherer Hofmeier; Sara Micaletto; Peter Schmid-Grendelmeier; Andreas Bircher; Dagmar Simon
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  Genetics and Molecular Biology of Epstein-Barr Virus-Encoded BART MicroRNA: A Paradigm for Viral Modulation of Host Immune Response Genes and Genome Stability.

Authors:  David H Dreyfus
Journal:  J Immunol Res       Date:  2017-04-28       Impact factor: 4.818

3.  Management of chronic urticaria in children: a clinical guideline.

Authors:  Carlo Caffarelli; Francesco Paravati; Maya El Hachem; Marzia Duse; Marcello Bergamini; Giovanni Simeone; Massimo Barbagallo; Roberto Bernardini; Paolo Bottau; Filomena Bugliaro; Silvia Caimmi; Fernanda Chiera; Giuseppe Crisafulli; Cristiana De Ranieri; Dora Di Mauro; Andrea Diociaiuti; Fabrizio Franceschini; Massimo Gola; Amelia Licari; Lucia Liotti; Carla Mastrorilli; Domenico Minasi; Francesca Mori; Iria Neri; Aurelia Pantaleo; Francesca Saretta; Carlo Filippo Tesi; Giovanni Corsello; Gian Luigi Marseglia; Alberto Villani; Fabio Cardinale
Journal:  Ital J Pediatr       Date:  2019-08-15       Impact factor: 2.638

4.  Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab".

Authors:  Ayman Abdelmaksoud; Mohamad Goldust; Michelangelo Vestita
Journal:  Int J Dermatol       Date:  2020-09-29       Impact factor: 3.204

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.